| News

BaseLaunch supports Switzerland as an innovation location

27.08.2019

Switzerland often receives awards for its innovative strength. Life sciences have generally played a huge part in this acclaim. The BaseLaunch accelerator operated by BaselArea.swiss is a major reason for innovation, a media report has found.

BaseLaunch

In its latest issue, the digital magazine “Pharma – Technology Focus” has dedicated an article to innovation in Switzerland. It explores the journey from startup to listed company and presents some of the success stories in the life sciences sector. The BaseLaunch accelerator operated by the innovation and economic promotion agency BaselArea.swiss is playing a key role in this development.

Almost two thirds of those in employed in the Swiss pharmaceutical sector work in the greater Basel area: 700 companies, more than 30,000 employees and R&D investment of 21 billion Swiss francs – these impressive figures are cited in the article. Industry activity is just one element of life sciences in Basel. The second is academic research, as director of BaseLaunch Stephan Emmerth explains, adding that more than 1,000 research groups and 13 research institutes are based in the region. Basel is therefore the perfect place for startups – and that’s where BaseLaunch comes into play.

The accelerator was founded in 2017 and is supported by the pharma giants Roche and Novartis. BaseLaunch helps startups launch and further develop their business models. This makes them attractive for venture capital funds and major pharma corporations, which invest as a result. “To do so, we offer grants of up to 250,000 francs and access to our partners,” said Stephan Emmerth. BaseLaunch has supported ten startups in this way to date, embedding them in the Basel area’s life sciences ecosystem.

In future, these companies could quite likely appear on the SIX Swiss Exchange. According to the magazine, SIX is the most important biotech exchange in Europe. The first major company from Basel to list on the exchange was Lonza in 1999 and Actelion a year later. After Johnson & Johnson took over Actelion, the spin-off Idorsia also decided to go public. They are considered pioneers, and the next company that follows in their footsteps could quite possibly have been helped on its way by BaseLaunch.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area – exactly the right chemistry for South Korean pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area – exactly the right chemistry for South Korean pharma companies

KPBMA and Basel Area Business & Innovation establish tailored collaboration to support Korean biopharmaceutical companies to enter the European market

Read More
Basel Area supporting three digital health startups
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Basel Area supporting three digital health startups

Basel Area Business & Innovation will be offering intensive support to the three winners of its DayOne Digital Health Accelerator...

Read More
Gray establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest

Gray establishes presence in Basel

The North American fully integrated specialty service provider Gray has established a subsidiary in Basel. The key factors in favor...

Read More
Artificial Intelligence able to identify potentially life-saving antibiotics
Basel Area Business & Innovation, Innovation, Invest

Artificial Intelligence able to identify potentially life-saving antibiotics

A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University...

Read More
Investors give Anaveon 110 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Investors give Anaveon 110 million Swiss francs

Anaveon has received investment commitments amounting to 110 million Swiss francs in a Serie B funding round. The Basel-based biopharmaceutical...

Read More
Basel alliance seeks to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest

Basel alliance seeks to combat antibiotic resistance

The Spearhead alliance has been founded in Basel with the aim of combating the silent pandemic of antimicrobial resistance. By...

Read More
Kinarus and Noorik awarded federal grants
Basel Area Business & Innovation, Innovation, Invest

Kinarus and Noorik awarded federal grants

The Basel-based biopharmaceutical companies Kinarus and Noorik have been awarded federal grants for their clinical trials investigating drug candidates to...

Read More
Alloy acquires deepCDR and will expand Basel site
Basel Area Business & Innovation, Innovation, Invest

Alloy acquires deepCDR and will expand Basel site

Alloy Therapeutics, a biotechnology firm from Boston in the USA, has acquired the Basel-based startup deepCDR Biologics. Alloy labs and...

Read More
Basel Healthtech fund successfully closed
Basel Area Business & Innovation, Innovation, Invest

Basel Healthtech fund successfully closed

The venture capital firm MTIP has announced the successful closing of its FUND II. It is one of the first...

Read More
Roche tests able to detect Omicron
Basel Area Business & Innovation, Innovation, Invest

Roche tests able to detect Omicron

The Roche subsidiary TIB Molbiol has developed new coronavirus testing kits that can also detect the new Omicron variant of...

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.